Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Borrego-Dorado I
  • Esteban-Figueruelo A
  • Gámez C
  • Hladun R
  • López-Almaraz R
  • Llempén ML
  • Rodado S
  • Rubio-Aparicio PM

Grupos

Abstract

Neuroblastoma (NB) is the most common extracranial solid cancer in children. Despite intensive multimodality treatment, long-term survival of patients with high-risk NB, which comprises more than half of all cases, remains poor. Nuclear medicine is key in diagnosis, staging, response assessment and long-term follow-up of NB. The emergence of novel tracers and the increasing complexity of studies require updated guidelines for nuclear medicine imaging in NB. Standardising diagnostic techniques are essential for improving study comparability and ensuring test quality. This article aims to provide a comprehensive review of NB radionuclide diagnostic imaging, including its characteristics, accuracy, advantages, and limitations. It offers practical recommendations to multidisciplinary teams responsible for treating patients with NB. This review summarises the opinions of leading experts from the Neuroblastoma Spanish Group within the Spanish Society of Paediatric Haematology and Oncology (SEHOP) and the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM).

© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Datos de la publicación

ISSN/ISSNe:
1699-048X, 1699-3055

Clinical & Translational Oncology  SPRINGER INT PUBL AG

Tipo:
Article
Páginas:
2401-2415
PubMed:
39508974
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,764 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 3

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • 3-Iodobenzylguanidine; Consensus; Diagnosis; Neuroblastoma; Positron-Emission Tomography; Radionuclide imaging

Cita

Compartir